These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
806 related articles for article (PubMed ID: 34925375)
1. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. Chen Y; Zheng X; Wu C Front Immunol; 2021; 12():792691. PubMed ID: 34925375 [TBL] [Abstract][Full Text] [Related]
4. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Kishore C; Bhadra P Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822 [TBL] [Abstract][Full Text] [Related]
5. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer. Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787 [TBL] [Abstract][Full Text] [Related]
6. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG Front Immunol; 2020; 11():620166. PubMed ID: 33584714 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in colorectal cancer. Agarwal P; Le DT; Boland PM Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613 [TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer. Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809 [TBL] [Abstract][Full Text] [Related]
9. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. Almquist DR; Ahn DH; Bekaii-Saab TS BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441 [TBL] [Abstract][Full Text] [Related]
10. Mechanism and strategies of immunotherapy resistance in colorectal cancer. Shan J; Han D; Shen C; Lei Q; Zhang Y Front Immunol; 2022; 13():1016646. PubMed ID: 36238278 [TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Xing R; Gao J; Cui Q; Wang Q Front Immunol; 2021; 12():783236. PubMed ID: 34899747 [TBL] [Abstract][Full Text] [Related]
12. Colorectal Cancer Immunotherapy: Options and Strategies. Johdi NA; Sukor NF Front Immunol; 2020; 11():1624. PubMed ID: 33042104 [TBL] [Abstract][Full Text] [Related]
13. T-cell-based immunotherapy in colorectal cancer. Feng M; Zhao Z; Yang M; Ji J; Zhu D Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958 [TBL] [Abstract][Full Text] [Related]
14. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Emambux S; Tachon G; Junca A; Tougeron D Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676 [TBL] [Abstract][Full Text] [Related]
15. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857 [TBL] [Abstract][Full Text] [Related]
16. The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy. Kamal Y; Schmit SL; Frost HR; Amos CI Immunotherapy; 2020 Oct; 12(14):1083-1100. PubMed ID: 32787587 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and predictive immunologic profile: the tip of the iceberg. Cunha Pereira T; Rodrigues-Santos P; Almeida JS; RĂªgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049 [TBL] [Abstract][Full Text] [Related]
18. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Thomas J; Leal A; Overman MJ Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280 [TBL] [Abstract][Full Text] [Related]
19. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]